{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:25:39Z","timestamp":1788294339504,"version":"build-2803163510"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.2169\/internalmedicine.3597-19","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T22:04:57Z","timestamp":1580508297000},"page":"345-355","source":"Crossref","is-referenced-by-count":22,"title":["Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients"],"prefix":"10.2169","volume":"59","author":[{"given":"Shogo","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Fukushima Prefectural Miyashita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukushima Prefectural Miyashita Hospital, Japan"},{"name":"Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukushima Prefectural Miyashita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukushima Prefectural Miyashita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kuro-o","sequence":"additional","affiliation":[{"name":"Division of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237: 18-27, 2008.","DOI":"10.1002\/dvdy.21388"},{"key":"2","unstructured":"2. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417-3428, 2007.","DOI":"10.1128\/MCB.02249-06"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997.","DOI":"10.1038\/36285"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Azuma M, Koyama D, Kikuchi J, et al. Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J 26: 4264-4274, 2012.","DOI":"10.1096\/fj.12-211631"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006.","DOI":"10.1074\/jbc.C500457200"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 98: 115-119, 2000.","DOI":"10.1016\/S0925-4773(00)00439-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687-26695, 2007.","DOI":"10.1074\/jbc.M704165200"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104: 7432-7437, 2007.","DOI":"10.1073\/pnas.0701600104"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006.","DOI":"10.1681\/ASN.2005111185"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.","DOI":"10.1172\/JCI200419081"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab 16: 693-705, 2012.","DOI":"10.1016\/j.cmet.2012.11.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425, 2007.","DOI":"10.1016\/j.cmet.2007.05.003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19: 1147-1152, 2013.","DOI":"10.1038\/nm.3249"},{"key":"15","unstructured":"15. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75: 503-533, 2013."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225, 2005.","DOI":"10.1016\/j.cmet.2005.09.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 9: 650-660, 2013.","DOI":"10.1038\/nrneph.2013.111"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1833, 2005.","DOI":"10.1126\/science.1112766"},{"key":"19","unstructured":"19. Xie T, Leung PS. Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol Endocrinol Metab 313: E292-E302, 2017."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Koyama D, Sato Y, Aizawa M, et al. Soluble alphaKlotho as a candidate for the biomarker of aging. Biochem Biophys Res Commun 467: 1019-1025, 2015.","DOI":"10.1016\/j.bbrc.2015.10.018"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Kario K, Saito I, Kushiro T, et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension 64: 989-996, 2014.","DOI":"10.1161\/HYPERTENSIONAHA.114.04262"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S; Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 61: 197-203, 2013.","DOI":"10.1053\/j.ajkd.2012.07.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mizuno H, Hoshide S, Fukutomi M, Kario K. Differing effects of aliskiren\/amlodipine combination and high-dose amlodipine monotherapy on ambulatory blood pressure and target organ protection. J Clin Hypertens (Greenwich) 18: 70-78, 2016.","DOI":"10.1111\/jch.12618"},{"key":"24","unstructured":"24. Mizuno H, Hoshide S, Tomitani N, Kario K. Comparison of ambulatory blood pressure-lowering effects of higher doses of different calcium antagonists in uncontrolled hypertension: the calcium antagonist controlled-release high-dose therapy in uncontrolled refractory hypertensive patients (CARILLON) study. Blood Press 26: 284-293, 2017."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296: 1313-1316, 2002.","DOI":"10.1126\/science.1070477"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603, 2004.","DOI":"10.1210\/en.2003-1671"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747, 2002.","DOI":"10.1210\/en.143.5.1741"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Wu AL, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 6: e17868, 2011.","DOI":"10.1371\/journal.pone.0017868"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Manna P, Achari AE, Jain SK. Vitamin D supplementation inhibits oxidative stress and upregulate SIRT1\/AMPK\/GLUT4 cascade in high glucose-treated 3T3L1 adipocytes and in adipose tissue of high fat diet-fed diabetic mice. Arch Biochem Biophys 615: 22-34, 2017.","DOI":"10.1016\/j.abb.2017.01.002"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. He JL, Zhao M, Xia JJ, et al. FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. Sci Rep 6: 29582, 2016.","DOI":"10.1038\/srep29582"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep 19: 28, 2017.","DOI":"10.1007\/s11906-017-0730-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kohara M, Masuda T, Shiizaki K, et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One 12: e0178971, 2017.","DOI":"10.1371\/journal.pone.0178971"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/3\/59_3597-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T20:31:39Z","timestamp":1665693099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/3\/59_3597-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3597-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}